Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 913048 | ISIN: FR0005175080 | Ticker-Symbol: TGNA
Stuttgart
05.06.25 | 10:49
1,015 Euro
-2,40 % -0,025
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRANSGENE SA Chart 1 Jahr
5-Tage-Chart
TRANSGENE SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,0301,04012:05

Aktuelle News zur TRANSGENE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTransgene S.A.: Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 20259
DiXFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2025120Das Instrument TGNA FR0005175080 TRANSGENE SA EO 0,50 EQUITY wird cum Kapitalmassnahme gehandelt am 03.06.2025 und ex Kapitalmassnahme am 04.06.2025 The instrument TGNA FR0005175080 TRANSGENE SA EO...
► Artikel lesen
MoNEC Corporation: Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 months with Individualized Cancer Vaccine TG4050432Strasbourg, France & Tokyo, Japan, June 2, 2025 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer...
► Artikel lesen
22.05.Transgene S.A.: Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 20256
15.05.Transgene S.A.: Transgene's Combined General Meeting of May 15, 20252
24.04.Transgene S.A.: Transgene Provides Business and Financial Update for Q1 2025156TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025 Dr. Simone Steiner appointed Chief Technical Officer (CTO) Business funded until the end of April 2026...
► Artikel lesen
24.04.Transgene S.A.: Availability of Preparatory Documents for the Combined General Meeting of May 15, 20253
TRANSGENE Aktie jetzt für 0€ handeln
23.04.Transgene S.A.: Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 20252
10.04.Transgene S.A.: Availability of Transgene's 2024 Universal Registration Document (URD)1
01.04.Transgene S.A.: Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations128Dr. Simone Steiner will focus on improving the manufacturing processes of individualized immunotherapies based on myvac® platform Strasbourg, France, April 1, 2025, 5:45 p.m. CET - Transgene (Euronext...
► Artikel lesen
27.03.Transgene S.A.: Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine - Strong Outlook for 20251802024 Full-year results and business update Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 Further data on 24-month follow-up...
► Artikel lesen
11.03.Transgene S.A.: Transgene to Participate in Upcoming Investor Meetings1
06.02.Transgene S.A.: Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts3
14.01.Transgene S.A.: Transgene Announces Financial Calendar for 20253
07.01.Transgene S.A.: Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 20243
07.11.24Transgene S.A.: Transgene Reports Business, Pipeline and Financial Update for Q3 2024526TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg...
► Artikel lesen
07.11.24Transgene S.A.: Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024793Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced...
► Artikel lesen
05.11.24Transgene S.A.: Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development181Strasbourg (France), Berlin (Germany), November 5, 2024, 7:30 a.m. CET-Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of...
► Artikel lesen
14.10.24Transgene S.A.: Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers154Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors...
► Artikel lesen
14.09.24Transgene S.A.: Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments657Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1